WHY IS IT ESSENTIAL TO KEEP THE PAP?
BECAUSE THEY’RE WORTH IT.1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1,2* Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.
WHY IS IT ESSENTIAL TO KEEP THE PAP?
BECAUSE THEY’RE WORTH IT.1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1,2* Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.
Hologic Women’s Health Diagnostics
When it comes to cervical cancer, if you want to provide complete care you need to administer complete testing. Hologic Women’s Health Diagnostics champions and provides essential cervical, sexual and vaginal testing by investing in advancing care standards, access and market-leading diagnostics.
Essential testing
Deliver maximum benefit to your patients by selecting our best-in-class, FDA-cleared molecular diagnostics and FDA-approved cytology products. This ensures you have relevant, accurate and reliable results to inform your decisions.
Optimal experience
We are invested in simplifying testing. This includes ordering, sample collection, EMR integration, understanding payor policy and continuing education. We want to provide the best possible experience for you and your patients across the continuum of care.
Partner in advocacy
As your specialized partner in cervical, sexual, and vaginal testing, we support you in navigating current policies and guidelines as well as advocate with you for advances in care standards. Because you are worth it as well.
Leading Cervical Cancer Prevention
For over 20 years, Hologic has been at the forefront of cervical cancer screening. Pap and human papillomavirus (HPV) testing are an essential component of our efforts in women’s health. With more than 650 million tests performed worldwide3, our ThinPrep Pap test has become the most widely used liquid-based cytology test3 — helping healthcare providers detect the presence of abnormal cervical cells4. While other HPV assays target DNA, our Aptima HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease. Furthermore, our Aptima HPV 16 18/45 genotype assay allows for the detection of
HPV types 16, 18 and 45, which together are associated with over 75% of all cancers and 94% of adenocarcinomas.5
1 in 5 women with Cervical Cancer were missed by Screening with HPV-Alone1,2*
- Studies show that 95% of cervical cancers are detected with Pap + HPV (co-testing)1,2
- 2x as many women with cervical cancer were missed with HPV-Alone* screening vs. Pap + HPV (co-testing)2
- Studies indicate between 9-31% of cervical cancers were HPV negative.1-2, 5-10
Pap + HPV Better Together
The Pap test, along with improvements in technology and advancements in cervical cancer screening guidelines, is credited with significantly decreasing cervical cancer death rates.11
Since the early 2000’s the recommended interval between screenings has increased. In 2012 the interval between screenings increased from 3-5 years. Now, for the first time in over 20 years there is an increase in cervical cancer incidence rates for women <50 years old.12
Co-testing Detects More Cervical Cancer Cases Than HPV-Based Screening
Recent publications representative of US clinical practice show Pap + HPV (co-testing) misses the fewest cancers/precursors to cancer:
Comparison of Three Longitudinal Co-Testing Studies
Quest Diagnostics: National reference laboratory
University of Pittsburgh Medical Center (UPMC): Large academic medical center
ACOG Guidelines Recommend Co-testing as the Preferred Method
ACOG recommends that for these women (ages 30-65):16
- Co-testing with cervical cytology and high-risk HPV testing every 5 years is preferred
- Screening with cervical cytology alone every 3 years is acceptable
- High-risk HPV testing alone can be considered as an alternative screening strategy
Contact us
Have a question or need to talk to a Hologic representative? Fill out the form below.
Disclaimer:
* A positive HPV screening result may lead to further evaluation with cytology and/or colposcopy.
References:
1. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/ cncy.21544 (Study included ThinPrep Pap Test, SurePath Pap Test and Hybrid Capture 2 assay). 2. Austin RM, et al. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Obstet Gynecol. 2018;150(5):385-392. doi:10.1093/ajcp/aqy114 (Study included ThinPrep Pap test, ThinPrep imaging, Digene HPV, Cervista HPV and Aptima HPV). 3. Hologic, Inc. Data on File. 4. ThinPrep 2000 Processor [instructions for use]. MAN-02624-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2017 5. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet. 2010;11(11):1048-56. doi:10.1015/S1470-2045(10)70230-8. 6. Katki HA, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663-672. doi:10.1016/S1470-2045(11)70145-0 (Study included conventional Pap, Hybrid Capture 2 assay). 7. Zhao Y, et al. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. J Med Virol. 2012;84:1920-1927. doi.org/10.1002/jmv.23353 8. Zhao C, et al. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia. Am J Clin Pathol 2013;140:47-54. doi.org/10.1309/AJCPIP9M8HPVBSSC 9. Zhao C, et al. Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012. Arch Pathol Lab Med. 2014;184-188. 10. Gage J, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8). doi:10.1093/jnci/ dju153 (Study included conventional Pap, Hybrid Capture® 2 assay) 11. American Cancer Society. Cancer Statistics Center. https://cancerstatisticscenter.cancer.org/?_ga=2.150839477.2044751383.1547156654-294386523.1544563210#!/. Accessed May 20, 2020. 12. North American Association of Central Cancer Registries. Fast Stats https://faststats.naaccr.org/selections.php?#Output Accessed May 20, 2020. 13. Hologic, Inc. Data on File. 14. Kaufman H, et al. Contributions of Liquid-based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV and Hybrid Capture 2). 15. Schiffman M, et al. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. J Natl Cancer Inst. 2018; 110(5):501-508. doi: 10.1093/jnci/djx225 (Study included conventional cytology, SurePath Pap test and Hybrid Capture 2). 16. American College of Obstetricians and Gynecologist. Women’s Health Care Physicians. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2018/08/cervical-cancer-screening-update. Released August 21, 2018. Accessed April 20, 2020.